The estimated Net Worth of William F Feehery is at least $58 Million dollars as of 1 April 2024. Dr Feehery owns over 69,799 units of Certara stock worth over $24,850,694 and over the last 13 years he sold CERT stock worth over $31,782,752. In addition, he makes $1,387,564 as CEO & Director at Certara.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr D CERT stock SEC Form 4 insiders trading
Dr has made over 17 trades of the Certara stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 69,799 units of CERT stock worth $766,393 on 1 April 2024.
The largest trade he's ever made was selling 145,000 units of Certara stock on 24 November 2021 worth over $4,122,350. On average, Dr trades about 28,213 units every 23 days since 2012. As of 1 April 2024 he still owns at least 2,263,269 units of Certara stock.
You can see the complete history of Dr Feehery stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. William F. Feehery Ph.D. biography
Dr. William F. Feehery Ph.D. is the CEO & Director at Certara.
What is the salary of Dr D?
As the CEO & Director of Certara, the total compensation of Dr D at Certara is $1,387,564. There are no executives at Certara getting paid more.
How old is Dr D?
Dr D is 50, he's been the CEO & Director of Certara since . There are 2 older and 3 younger executives at Certara. The oldest executive at Certara, Inc. is Leif E. Pedersen, 57, who is the Pres of Software.
What's Dr D's mailing address?
William's mailing address filed with the SEC is 530 HERMAN O. WEST DRIVE, , EXTON, PA, 19341.
Insiders trading at Certara
Over the last 5 years, insiders at Certara have traded over $2,048,278,243 worth of Certara stock and bought 97,245 units worth $1,908,085 . The most active insiders traders include Avatar Parent L.P.Eqt Avata..., James E Iii Cashman, and Mason P Slaine. On average, Certara executives and independent directors trade stock every 14 days with the average trade being worth of $7,828,136. The most recent stock trade was executed by Leif E Pedersen on 9 September 2024, trading 51,224 units of CERT stock currently worth $578,319.
What does Certara do?
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
What does Certara's logo look like?
Complete history of Dr Feehery stock trades at West Pharmaceutical Services and Certara
Certara executives and stock owners
Certara executives and other stock owners filed with the SEC include:
-
Dr. William F. Feehery Ph.D.,
CEO & Director -
M. Andrew Schemick,
Chief Financial Officer -
Leif E. Pedersen,
Pres of Software -
Jaap Mandema,
Chief Innovation Officer -
Nicolette D. Sherman,
Chief HR Officer -
Ron DiSantis,
Sr. VP of Corp. Devel. -
Jieun W. Choe,
Chief Strategy & Marketing Officer -
Richard M. Traynor,
Sr. VP & Gen. Counsel -
Prof. Amin Rostami PharmD, Ph.D., FCP,
Chief Scientific Officer -
Andrew Schemick,
Chief Financial Officer -
Drayton Virkler,
PRESIDENT, REG & ACCES -
Patrick F Smith,
PRESIDENT, DRUG DEV SOLUTIONS -
Rona Anhalt,
Chief Human Resources Officer -
Daniel Corcoran,
SVP and General Counsel -
Eran Broshy,
-
Avatar Parent L.P.Eqt Avata...,
-
Stephen M. Mc Lean,
-
Judith Dickinson,
See Remarks -
Justin Edge,
PRES., REGULATORY & ACCESS -
William F Feehery,
CHIEF EXECUTIVE OFFICER -
Sherilyn S Mc Coy,
Director -
Richard M. Traynor,
SVP AND GENERAL COUNSEL -
Carol Giltner Gallagher,
-
Craig R. Rayner,
PRESIDENT, INTEGRATED DRUG DEV -
Robert Aspbury,
PRESIDENT, SCIENTIFIC SOFTWARE -
Nicolette D Sherman,
CHIEF HUMAN RESOURCES OFFICER -
Cynthia Collins,
-
Nancy Killefer,
-
Jieun W. Choe,
CHIEF STRATEGY & MARKETING -
James E Iii Cashman,
-
Mason P Slaine,
-
Rosemary A Crane,
-
Matthew M Walsh,
-
John E Gallagher,
CHIEF FINANCIAL OFFICER -
Leif E Pedersen,
PRESIDENT, CHIEF COMMERCAL OFF